FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

20549
•

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ianchulev Tsontcho</u>						2. Issuer Name and Ticker or Trading Symbol EYENOVIA, INC. [EYEN]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner							
	ENOVIA, II		(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/24/2020									X Officer (give title Other (specify below) Chief Executive Officer						
295 MADISON AVENUE, SUITE 2400						4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applica													icable		
(Street) NEW YO	reet) EW YORK NY 10017								9		(X Form filed by One Reporting Person Form filed by More than One Reporting								
(City)	(S	State)	tate) (Zip)										Person								
		Ta	able I - No	n-Deriv	/ati	ve S	ecurities	s Ac	quired,	Dis	posed o	f, or Ber	neficia	ally (Owned						
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/		Execution		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			d 5)	Securities Beneficiall Owned Fo	Beneficially Dwned Following		Direct Indirect Etr. 4)	. Nature of ndirect eneficial bwnership		
						Code V Amo		Amount	Amount (A) or (D)			Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)					
Common	n Stock, par value \$.0001			03/24/2020				P		82,431 A		\$2.2	27 ⁽¹⁾	508,679		D					
Common Stock, par value \$.0001												606,667		I		By Private Medical Equity, nc. ⁽²⁾					
Common	Stock, par	value \$.0001											6,000			00		I By The Meliora Trust ⁽²⁾			
Common Stock, par value \$.0001														453,333			I S F	By PME nvestor services Syenovia, LLC ⁽²⁾			
			Table II -												wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Tr	te, Transact		5. Number of 6 saction Derivative			xerci:	sable and e	of Securities		nt	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amour or Number of Sha	er		Transact (Instr. 4)	ion(s)				
Class A Warrant	\$2.27 ⁽³⁾	03/24/2020			P		41,216 ⁽⁴⁾		03/24/20)20	03/24/2021	Common Stock	41,2	16	(1)	41,2	16	D			
Class B Warrant	\$2.724 ⁽³⁾	03/24/2020			P		61,823 ⁽⁴⁾		03/24/20)20	03/24/2025	Common Stock	61,8	23	(1)	61,82	23	D			
Stock Option (right to buy)	\$1.95								(5)		07/07/2027	Common Stock	267,3	570		267,370		D			
Stock Option (right to buy)	\$6.2								(6)		07/24/2028	Common Stock	124,2	10		124,2	10	D			
Stock Option (right to buy)	\$3.11								(7)		08/16/2029	Common Stock	183,7	03		183,703		D			
Stock Option (right to buy)	\$1.24								03/23/20)15	03/23/2025	Common Stock	140,0	00		140,0	00	I	By Private Medical Equity, Inc. (2)		

- 1. On March 24, 2020, the Reporting Person purchased Units from the Issuer in a private placement, with each Unit consisting of (a) one share of the Issuer's common stock, (b) a Class A Warrant representing the right to acquire 0.75 shares of the Issuer's common stock. The purchase price for each Unit was \$2.42625 of which \$2.27 was for the Issuer's common stock, \$0.06250 was for the Class A Warrant and \$0.09375 was for the Class B Warrant.
- 2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- 3. The exercise price per share of the Issuer's common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events.
- 4. The number of shares of Issuer common stock issuable upon exercise of the Class A and Class B Warrants is subject to adjustment for stock splits, stock dividends and similar corporate events.
- $5. \ The option became exercisable as to 11,140 \ shares on August 7, 2017 \ and becomes exercisable in equal 11,140 \ share amounts on each of the 35 one-month anniversaries thereafter.$

6. This option is fully vested.

7. One-third of the option becomes exercisable on August 16, 2020 and the remaining shares underlying the option become exercisable in equal increments on each of the 24 one-month anniversaries thereafter.

/s/ S. Halle Vakani, Attorney-in-03/26/2020

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.